



YOU WEREN'T MADE
FOR MODERATE TO SEVERE
ULCERATIVE COLITIS OR
CROHN'S DISEASE.

BUT ENTYVIO IS.



Ask your doctor about ENTYVIO.

ENTYVIO has helped many people achieve long-term relief and remission. It may help you too. Individual results may vary.

Uses of ENTYVIO® (vedolizumab):

ENTYVIO is a prescription medicine used in adults for the treatment of:

- moderately to severely active ulcerative colitis
- moderately to severely active Crohn's disease

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see full Important Safety Information and Prescribing Information on page 8.



WHY CONSIDER ENTYVIO?

Here are a few things for you and your doctor to discuss about ENTYVIO:




ENTYVIO helped patients achieve long-term relief and remission.

See pages 3-4 for clinical studies.

Inside:

Clinical Study Results: Ulcerative Colitis.....	3
ENTYVIO Compared to HUMIRA®* (adalimumab).....	3
Clinical Study Results: Crohn's Disease.....	4
How ENTYVIO Works.....	5
Real Patient Experiences.....	6
Starting ENTYVIO.....	7
Full Important Safety Information.....	8
Support from <i>EntyvioConnect</i>	9
Speaking with Your Doctor.....	11



ENTYVIO is gut focused.

ENTYVIO works at the site of the problem to block certain inflammation-causing cells from entering the gut.

See page 5 for how it works.



ENTYVIO and HUMIRA®* (adalimumab) went head-to-head in a study of patients with moderate to severe ulcerative colitis.

See page 3 for results.

Individual results may vary.

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see full Important Safety Information and Prescribing Information on page 8.

*Humira is a registered trademark of AbbVie Inc., North Chicago, IL. For information related to adalimumab, please see AbbVie.com.



ENTYVIO DELIVERED RESULTS FOR PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

In clinical studies, ENTYVIO delivered results for adult patients with moderate to severe ulcerative colitis when other medicines had not worked well enough or could not be tolerated.

Early Results



47% of patients on ENTYVIO achieved response* compared to 26% of patients on placebo at Week 6.

Long-term Remission†



42% of patients achieved remission compared to 16% of patients on placebo at 1 year.

Individual results may vary.

Ask your doctor if ENTYVIO is right for you.

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see full Important Safety Information and Prescribing Information on page 8.



Visit [ENTYVIO.com/UC](https://www.entyvio.com/UC) to learn more

How ENTYVIO compared to HUMIRA®† (adalimumab) in patients with moderate to severe ulcerative colitis



In a separate head-to-head study, ENTYVIO helped significantly more adult patients with moderate to severe ulcerative colitis than HUMIRA®* (adalimumab) achieve remission at 1 year.

31.3% of ENTYVIO patients achieved remission compared to 22.5% of Humira patients at 1 year.

The reported side effects of ENTYVIO in this study were consistent with previous clinical studies. No new safety signals were seen for ENTYVIO. The study was not designed to compare safety profiles.

*Response is a measure to determine improvement of the patient's UC symptoms and condition.

†Remission is a measure to determine when a patient with UC is experiencing a few to no symptoms and an improvement in their condition.

In the ENTYVIO clinical studies, clinical response and remission was defined and measured by improvement in the Mayo score, an assessment tool that measures stool frequency, rectal bleeding, appearance of the mucosal lining of the colon, and physician assessment.

†Humira is a registered trademark of AbbVie, Inc. For information related to adalimumab, please see [AbbVie.com](https://www.abbvie.com).



ENTYVIO HELPED PATIENTS WITH CROHN'S DISEASE ACHIEVE REMISSION

In clinical studies, ENTYVIO delivered results for adult patients with moderate to severe Crohn's disease when other medicines had not worked well enough or could not be tolerated.

Early Results



15% of patients achieved remission as early as Week 6 compared to 7% of patients on placebo.*

Long-term Remission



39% of patients achieved remission at 1 year compared to 22% of patients on placebo.


Individual results may vary.

Ask your doctor if ENTYVIO is right for you.

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see full Important Safety Information and Prescribing Information on page 8.



Visit [ENTYVIO.com/CD](https://www.entyvio.com/CD) to learn more

Steroid-free Remission



Twice as many patients with Crohn's disease taking ENTYVIO achieved remission without depending on steroids versus patients on placebo at 1 year.

Individual results may vary.

*Remission is a measure to determine when a patient with Crohn's disease is experiencing a few to no symptoms and an improvement in their condition. In the ENTYVIO clinical studies, clinical remission was defined and measured by improvement in the CDAI score, a tool that assesses the number of liquid or very soft stools, abdominal pain, and other measures of disease activity.

What causes ulcerative colitis and Crohn's disease?

Your immune system uses white blood cells to protect you from infections and other diseases. In people who have UC or Crohn's disease, the immune system mistakenly identifies certain parts of your gut as invasive material and sends too many white blood cells to the area. This causes increased inflammation, which can result in permanent damage to your gut.

How does ENTYVIO work?

ENTYVIO works by blocking a type of gut-directed, inflammation-causing white blood cell from entering the gut. This can help control inflammation seen in ulcerative colitis and Crohn's disease.

What are white blood cells?



White blood cells are part of your immune system. They help your body fight off infections and other diseases.

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see full Important Safety Information and Prescribing Information on page 8.

In ulcerative colitis and Crohn's disease:

Overactive immune system sends **too many white blood cells** into the gut



White blood cells can cause inflammation

With ENTYVIO:

Overactive immune system sends **too many white blood cells** into the gut



ENTYVIO BLOCKS certain white blood cells from entering the gut, helping to control inflammation

Learn more about the science of ENTYVIO at HowENTYVIOWorks.com.

WHAT REAL PATIENTS ARE SAYING

Living with moderate to severe ulcerative colitis or Crohn's disease brings its challenges. But for these patients, ENTYVIO has made a difference.

Individual results may vary.

“I have been on ENTYVIO for years now. Once every year I reach out to *EntyvioConnect* to renew my services.”



Ron: Patient with Severe Ulcerative Colitis

Real people. Real-life experiences.

Want to talk to someone who knows the experiences of living with Crohn's or ulcerative colitis firsthand? The Entyvio Connections program can connect you with our patient ambassadors for insight and encouragement.

Call **1-833-492-8847** or visit [UCCDmentorprogram.com](https://www.entyvio.com/uccdmentorprogram) to register for Entyvio Connections.

“When my doctor told me about ENTYVIO, I didn't think I could try one more treatment. After some time on ENTYVIO, I responded well and achieved remission.”



Jen: Patient with Severe Crohn's Disease

Hear more insights from these patients and others at [ENTYVIO.com/PatientStories](https://www.entyvio.com/PatientStories)

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see full Important Safety Information and Prescribing Information on page 8.

STARTING ENTYVIO

ENTYVIO is administered by a healthcare provider through a needle placed in a vein in your arm (intravenously), either at the healthcare provider's office or at an alternate site of care.

Your infusion should take about 30 minutes, and your healthcare provider will monitor you during and after the ENTYVIO infusion for side effects to see if you have a reaction to the treatment.

Treatment Schedule

Starting Doses



WEEK 0



WEEK 2



WEEK 6

You will receive ENTYVIO by infusion at **Weeks 0, 2, and 6.**

Maintenance Doses



EVERY 8 WEEKS

Starting at **Week 14**, you'll receive **1 infusion every 8 weeks.**

- **In the first year**, you'll receive 8 doses of ENTYVIO
- **After the first year**, you'll receive 6 doses each year



Hear real patients talk about what it's like to receive an infusion at [ENTYVIO.com/PatientStories](https://www.entyvio.com/PatientStories)

The Infusion Takes About 30 Minutes



If you have questions about the infusion process, speak with your doctor.

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see full Important Safety Information and Prescribing Information on page 8.

Important Safety Information for ENTYVIO® (vedolizumab)

- Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients.
- ENTYVIO may cause serious side effects, including:
 - Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. You may need treatment if you have an allergic reaction. Tell your healthcare provider or get immediate medical help if you get any of these symptoms during or after an infusion of ENTYVIO: rash, itching, swelling of your lips, tongue, throat or face, shortness of breath or trouble breathing, wheezing, dizziness, feeling hot, or palpitations (feel like your heart is racing).
 - ENTYVIO may increase your risk of getting a serious infection. Before receiving and during treatment with ENTYVIO, tell your healthcare provider if you think you have an infection or symptoms of an infection, such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, red or painful skin or sores on your body, tiredness, or pain during urination.
 - People with weakened immune systems can get progressive multifocal leukoencephalopathy (PML) (a rare, serious brain infection caused by a virus). Although unlikely while receiving ENTYVIO, a risk of PML cannot be ruled out. PML can result in death or severe disability. There is no known treatment, prevention, or cure for PML. Tell your healthcare provider right away if you have any of the following symptoms: confusion or problems thinking, loss of balance, change in the way you walk or talk, decreased strength or weakness on one side of the body, blurred vision, or loss of vision.
 - Liver problems can happen in people who receive ENTYVIO. Tell your healthcare provider right away if you have any of the following symptoms: tiredness, loss of appetite, pain on the right side of your abdomen, dark urine, or yellowing of the skin and eyes (jaundice).

Important Safety Information for ENTYVIO® (vedolizumab) (continued)

- The most common side effects of ENTYVIO include common cold, headache, joint pain, nausea, fever, infections of the nose and throat, tiredness, cough, bronchitis, flu, back pain, rash, itching, sinus infection, throat pain, and pain in extremities. These are not all the possible side effects of ENTYVIO. Call your healthcare provider for medical advice about side effects.
- Before receiving ENTYVIO, tell your healthcare provider about all of your medical conditions, including if you: have or think you may have an infection or have infections that keep coming back; have liver problems; have tuberculosis (TB) or have been in close contact with someone with TB; have recently received or are scheduled to receive a vaccine; or if you are pregnant, breastfeeding, plan to become pregnant, or plan to breastfeed.

Please see full Prescribing Information, including the Medication Guide, for ENTYVIO, and talk with your healthcare provider.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Uses of ENTYVIO® (vedolizumab)

ENTYVIO is a prescription medicine used in adults for the treatment of:

- moderately to severely active ulcerative colitis
- moderately to severely active Crohn's disease

EXPERT HELP WHEN YOU NEED IT MOST


Living with ulcerative colitis or Crohn's disease is difficult enough. Managing your treatment shouldn't be. Once you and your doctor have made the decision to try ENTYVIO, the caring team of experts at *EntyvioConnect* is available to guide you with resources designed to make your journey as stress-free as possible.

Once you're prescribed ENTYVIO, you're eligible for *EntyvioConnect*.



PERSONALIZED GUIDANCE

When you enroll in *EntyvioConnect*, you'll be paired with a Nurse Educator who will reach out to you and be your go-to person for answers and support about ENTYVIO. While nurses can't give personalized medical advice, they can provide guidance to help you make the most out of every checkup you have with your doctor.



FINANCIAL AND INSURANCE HELP

A specialist can walk you through the process step-by-step and help you navigate copay assistance and out-of-pocket costs, so you understand what's covered, what's not, and what to do next. If you have commercial insurance through your employer or family member, we'll work with you to see if you're eligible for our Co-Pay Program. If you qualify, you may pay as little as \$5 per dose every 8 weeks.*

*Must meet eligibility requirements



Patient and healthcare professional portrayals



ONGOING SUPPORT

You can sign up to receive additional information or schedule helpful medication reminders. Whether you receive ENTYVIO at an infusion center, your doctor's office, or at home, our text reminders can help you stay on track.

GET CONNECTED

Call **1-844-ENTYVIO** (1-844-368-9846) or sign up at: [ENTYVIO.com/Connect](https://www.entyvio.com/Connect).

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see full Important Safety Information and Prescribing Information on page 8.

GET READY FOR YOUR DOCTOR VISIT

The questions below can help get your conversation started as you and your doctor explore potential treatment options for your condition. Fill out this page, and bring it with you to your next appointment.

How many bowel movements do you have a day?

1
 2
 3
 4
 5
 6
 7
 8
 9
 10+

Have you experienced any weight loss?

Yes
 No

How often do you experience any of the following symptoms?

Abdominal pain or cramping

Never
 Occasionally
 Sometimes
 Often
 Always

Diarrhea

Never
 Occasionally
 Sometimes
 Often
 Always

Rectal bleeding

Never
 Occasionally
 Sometimes
 Often
 Always

Accidents

Never
 Occasionally
 Sometimes
 Often
 Always

Constipation

Never
 Occasionally
 Sometimes
 Often
 Always

Straining during bowel movements

Never
 Occasionally
 Sometimes
 Often
 Always

Lack of energy

Never
 Occasionally
 Sometimes
 Often
 Always

Please indicate how you feel using the following scale:

Terrible

 Okay

 Good

What, if any, treatments are you currently using?

Are your current treatments working well enough?

Yes
 No

This is a sample dialogue. It is not, nor is it intended to be, a medical evaluation, examination, advice, consultation, diagnosis, or treatment. Always consult your healthcare professional for all medical and health-related matters.




QUESTIONS TO ASK YOUR DOCTOR

Here are some examples of questions you may want to ask your doctor as you work together to find the best treatment for your specific needs.

How is a biologic medication different from other medications?

Have there been clinical studies that show how biologic treatment options for ulcerative colitis compare to other treatments?

When can I expect to start feeling better?




Patient and healthcare professional portrayals

What goals should I set for my treatment?

Could ENTYVIO be right for me?

INTESTINE DAMAGED BY ULCERATIVE COLITIS




While both ulcerative colitis and Crohn's disease are types of inflammatory bowel disease, the effects of ulcerative colitis are limited to the large intestine, which includes the ascending colon, transverse colon, descending colon, and rectum.

Unlike Crohn's disease, which can affect all layers of the bowel wall, ulcerative colitis affects only the innermost lining of the colon.

Notes: _____

INTESTINE DAMAGED BY CROHN'S DISEASE



Crohn's disease most commonly affects the end of the small bowel (the ileum) and the beginning of the colon.

Crohn's disease can affect the thickness of the bowel wall in any part of the GI tract and the inflammation it causes can "skip"—leaving normal areas in between patches of diseased intestine.



For adults with moderate to severe ulcerative colitis or Crohn's disease when current treatment is not working well enough or cannot be tolerated.




Ask your doctor about ENTYVIO today

EXPLORE ENTYVIO



ENTYVIO helped patients achieve long-term relief and remission.

Individual results may vary.



ENTYVIO works at the site of the problem to block certain inflammation-causing cells from entering the gut.

Please see full Important Safety Information and Prescribing Information on page 8.

To learn more about ENTYVIO, call **1-844-ENTYVIO** or go to [ENTYVIO.com/SignUp](https://www.entyvio.com/signup) and follow us on social media.



ENTYVIO and the ENTYVIO logo are registered trademarks of Millennium Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.